Scholar Rock resubmits marketing authorisation application for apitegromab with EMA to treat children and adults with spinal muscular atrophy
Scholar Rock, a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin
Full article text belongs to the original publisher. Moogle News shows the headline/summary and sends you to the source.
Read full story on publisher site →